Hikma Pharmaceuticals plc (LSE:HIK) agreed to acquire Egyptian Company for Pharmaceuticals & Chemical Industries from a consortium of shareholders for approximately EGP 130 million on January 9, 2013. The deal is expected to close on or before February 14, 2013 and is conditional on fulfillment of conditions precedent. HC Securities and Investment acted as financial advisor to Hikma on the deal.

Ben Atwell, Julia Phillips, Jonathan Birt and Matthew Cole of FTI Consulting acted as PR advisors to Hikma Pharmaceuticals.